Eli Lilly and Boehringer drug gets head start at FDA
Jardiance has been awarded "priority review" status by the US Food and Drug Administration in a new indication.
by marketwire, translated by catherine brett
Eli Lilly and its partner Boehringer Ingelheim have been granted special status at the FDA for their drug Jardiance, to speed up its journey to market as a preventive therapy for heart failure in patients who are not suffering from reduced ventricle functioning.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
New study provides good results for Eli Lilly and Boehringer
For subscribers
